CABA - Cabaletta Bio Inc logo

CABA

Cabaletta Bio Inc

Rev โ€”top 1%5Y
Hold

Cabaletta Bio develops engineered T cell therapies for autoimmune diseases, focusing on resecabtagene autoleucel for conditions like dermatomyositis and lupus. Its pipeline includes therapies for mucosal pemphigus vulgaris and myasthenia gravis.

โš•๏ธ Healthcare NASDAQ Listed 2019 $ USD
$1,000 invested 5 years ago โ†’$363today

Score Overview

1 Year
Scoreโ€”
Net Growth-4.51%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-285.29%
Net TrendNever
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-9x
Net TrendNever
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

See the full market ranking โ†’

Cabaletta Bio Inc fundamental performance

Across Cabaletta Bio Inc's full reported history, from 2019 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 15M to -$ 167M. Revenue increased in 0% of the years measured; net income in 0%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-13
$ 2.71โ€”
1 Year2025-08-13
$ 1.7158.48%
5 Years2021-08-13
$ 7.46-63.67%
All Time2019-10-25
$ 10.00-72.90%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 175M$ 116M
2025$ 0.00-$ 167M$ 133M
2024$ 0.00-$ 115M$ 163M
2023$ 0.00-$ 67M$ 241M
2022$ 0.00-$ 51M$ 106M
2021$ 0.00-$ 45M$ 122M
2020$ 0.00-$ 32M$ 108M
IPO2019$ 0.00-$ 15M$ 136M

Explore beyond CABA

You're looking at Cabaletta Bio Inc. Members apply the same fundamental framework across all 3,859 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies